- Home
- LUCK vs NRIX Comparison
LUCK vs NRIX Comparison
Compare LUCK & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCK
- NRIX
- Stock Information
- Founded
- LUCK 1997
- NRIX 2009
- Country
- LUCK United States
- NRIX United States
- Employees
- LUCK N/A
- NRIX N/A
- Industry
- LUCK
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- LUCK
- NRIX Health Care
- Exchange
- LUCK NYSE
- NRIX Nasdaq
- Market Cap
- LUCK 1.2B
- NRIX 1.1B
- IPO Year
- LUCK N/A
- NRIX 2020
- Fundamental
- Price
- LUCK $9.10
- NRIX $12.78
- Analyst Decision
- LUCK Buy
- NRIX Strong Buy
- Analyst Count
- LUCK 2
- NRIX 17
- Target Price
- LUCK $13.00
- NRIX $30.71
- AVG Volume (30 Days)
- LUCK 288.7K
- NRIX 844.8K
- Earning Date
- LUCK 05-08-2025
- NRIX 07-10-2025
- Dividend Yield
- LUCK 2.42%
- NRIX N/A
- EPS Growth
- LUCK N/A
- NRIX N/A
- EPS
- LUCK N/A
- NRIX N/A
- Revenue
- LUCK $1,184,019,000.00
- NRIX $56,417,000.00
- Revenue This Year
- LUCK $6.36
- NRIX $15.43
- Revenue Next Year
- LUCK $5.94
- NRIX N/A
- P/E Ratio
- LUCK N/A
- NRIX N/A
- Revenue Growth
- LUCK 6.65
- NRIX N/A
- 52 Week Low
- LUCK $7.66
- NRIX $8.18
- 52 Week High
- LUCK $14.92
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- LUCK N/A
- NRIX 70.71
- Support Level
- LUCK N/A
- NRIX $11.92
- Resistance Level
- LUCK N/A
- NRIX $12.59
- Average True Range (ATR)
- LUCK 0.00
- NRIX 0.64
- MACD
- LUCK 0.00
- NRIX 0.37
- Stochastic Oscillator
- LUCK 0.00
- NRIX 92.17
About LUCK LUCKY STRIKE ENTERTAINMENT CORPORAT
Lucky Strike Entertainment Corp is a entertainment platforms. It has nearly 360 locations across North America, that provides experiential offerings in bowling, amusements, water parks, and family entertainment centers. The company also owns the Professional Bowlers Association, the league of bowling and a growing media property.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.